



## (51) International Patent Classification:

C07D 471/04 (2006.01) A61P 17/00 (2006.01)  
A61K 31/437 (2006.01) A61P 27/02 (2006.01)  
A61P 11/00 (2006.01)

## (21) International Application Number:

PCT/US2018/030148

## (22) International Filing Date:

30 April 2018 (30.04.2018)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/492,574 01 May 2017 (01.05.2017) US

## (71) Applicant: THERAVANCE BIOPHARMA R&amp;D IP, LLC [US/US]; 901 Gateway Boulevard, South San Francisco, California 94080 (US).

(72) Inventors: FATHEREE, Paul R.; 921 Minnesota Street, San Francisco, California 94107 (US). JIANG, Lan; 788 Santa Maria Lane, Foster City, California 94404 (US). MCKINNELL, Robert Murray; 321 Poplar Avenue, Millbrae, California 94030 (US). THALLADI, Venkat R.; 888 Foster City Boulevard, Apt. E3, Foster City, California 94404 (US). ZHANG, Hao; 1025 Jamaica Street, Foster City, California 94404 (US). DABROS, Marta; 888 Foster City Boulevard, Apt. Q2, Foster City, California 94404 (US). NZEREM, Jerry; 29 Woods Circle, South San Francisco, California 94080 (US). BENJAMIN, Noah; 2120 24th Street, Unit 5, San Francisco, California 94107 (US). KLEINSCHEK, Melanie A.; 30 Elizabeth Street, San Francisco, California 94110 (US). CRATER, Glenn D.; 7108 Rippling Stone Ln, Raleigh, North Carolina 27612 (US).

(74) Agent: HAGENAH, Jeffrey A. et al.; THERAVANCE, INC., 901 Gateway Boulevard, South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,


CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report (Art. 21(3))

(54) Title: FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND



(1)

(57) Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.

